About cosciens biopharma - AEZS
COSCIENS Biopharma Inc. Is a specialty biopharmaceutical company, which engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Canada.
AEZS At a Glance
COSCIENS Biopharma, Inc.
222 Bay Street
Toronto, Ontario M5K 1E7
| Phone | 1-843-900-3223 | Revenue | 4.50M | |
| Industry | Pharmaceuticals: Major | Net Income | -16,552,000.00 | |
| Sector | Health Technology | Employees | 21 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
AEZS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.104 |
| Price to Book Ratio | 0.52 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 1.361 |
| Enterprise Value to Sales | -5.396 |
| Total Debt to Enterprise Value | -0.011 |
AEZS Efficiency
| Revenue/Employee | 214,190.476 |
| Income Per Employee | -788,190.476 |
| Receivables Turnover | 13.114 |
| Total Asset Turnover | 0.097 |
AEZS Liquidity
| Current Ratio | 8.01 |
| Quick Ratio | 7.996 |
| Cash Ratio | 7.493 |
AEZS Profitability
| Gross Margin | 91.307 |
| Operating Margin | -400.356 |
| Pretax Margin | -367.986 |
| Net Margin | -367.986 |
| Return on Assets | -35.58 |
| Return on Equity | -61.336 |
| Return on Total Capital | -89.591 |
| Return on Invested Capital | -61.127 |
AEZS Capital Structure
| Total Debt to Total Equity | 1.533 |
| Total Debt to Total Capital | 1.51 |
| Total Debt to Total Assets | 0.754 |
| Long-Term Debt to Equity | 0.654 |
| Long-Term Debt to Total Capital | 0.644 |